Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Randomized, Double-Blind Study Comparing the Safety Efficacy of ABT-874 to Methotrexate in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Next Previous
Trial Profile

A Phase 3, Multicenter, Randomized, Double-Blind Study Comparing the Safety Efficacy of ABT-874 to Methotrexate in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Briakinumab (Primary) ; Methotrexate
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Sponsors Abbott Laboratories

Most Recent Events

  • 06 Oct 2017 Results (n=273) of a post hoc retrospective analysis developing and validating a prediction rule to identify patients unlikely to respond adequately to methotrexate using patient data from NCT00235820 and NCT00679731 trials published in the Journal of the American Academy of Dermatology
  • 08 Mar 2016 Results (n=849) of a pooled subgroup analysis from this and two other trials (see profile 40201 and 255049) presented at the 74th Annual Meeting of the American Academy of Dermatology
  • 08 Mar 2016 Results (pooled subgroup analysis of this and other 3 phase III studies, n = 1558) presented at the 74th Annual Meeting of the American Academy of Dermatology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top